Enliven Therapeutics, Inc. has disclosed significant stock transactions involving its director Garland J. Scott. The report, filed on October 5, 2026, details both the acquisition and sale of shares, which could reflect strategic decisions within the company.
Enliven Therapeutics, Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, is a publicly traded company on the Nasdaq under the ticker ELVN. The company focuses on developing innovative therapies and has been active in the market, as evidenced by its recent filings.
The filing reveals that on October 1, 2026, Garland J. Scott acquired 13,000 shares of common stock at a price of $15.47 per share. Additionally, the director sold 13,000 shares at a weighted average price of $46.67, which was executed through multiple trades. Following these transactions, Scott currently holds 46,372 shares of the company.
"This transaction was executed in multiple trades at prices ranging from $46.62 to $46.87," the filing states.
The transactions could impact shareholders and potential investors as they may signal the director's confidence in the company's direction or a response to market conditions. The pharmaceutical preparations industry is known for its volatility and rapid changes, making such insider activity particularly noteworthy.
The filing does not specify what actions may follow these transactions, leaving stakeholders to speculate on future developments.